OMAHA, Neb. – Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions announce today their available services for GlaxoSmithKline’s infused medication sotrovimab. Sotrovimab is a monoclonal antibody treatment that has received the FDA’s emergency use authorization, or EUA, for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
Sotrovimab is authorized to treat patients (12 years of age and older weighing at least 88 lbs) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Sotrovimab marks the third monoclonal antibody treatment that Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions are able to offer patients.
“Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions continue to be proud of the role we play in supporting COVID-19 healthcare workers and patients throughout the country. We are committed to positively impacting the communities we serve,” said Kristin Williams, President of Amber Specialty Pharmacy and Chief Health Officer at Hy-Vee, Inc.
Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions, subsidiaries of Hy-Vee, Inc., have 21 locations throughout the U.S. All locations are licensed to administer the antibody treatment and are able to service patients in all 50 states and Puerto Rico.